Vantage Consulting Group Inc boosted its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 18.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 3,648 shares of the biopharmaceutical company’s stock after buying an additional 576 shares during the period. Vantage Consulting Group Inc’s holdings in Bristol-Myers Squibb were worth $253,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $1,873,696,000. Moneta Group Investment Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 114,228.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after purchasing an additional 21,451,006 shares during the last quarter. Boston Partners boosted its holdings in shares of Bristol-Myers Squibb by 31.1% during the 1st quarter. Boston Partners now owns 18,080,568 shares of the biopharmaceutical company’s stock valued at $1,252,480,000 after purchasing an additional 4,286,479 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Bristol-Myers Squibb by 7.7% during the 1st quarter. Nordea Investment Management AB now owns 12,074,501 shares of the biopharmaceutical company’s stock valued at $833,986,000 after purchasing an additional 863,174 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 11,207,099 shares of the biopharmaceutical company’s stock valued at $806,351,000 after purchasing an additional 70,887 shares during the last quarter. Hedge funds and other institutional investors own 74.57% of the company’s stock.

Get Bristol-Myers Squibb alerts:

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. 51job reissued a “maintains” rating on shares of Bristol-Myers Squibb in a report on Friday, April 28th. Barclays lowered their price target on shares of Bristol-Myers Squibb from $64.00 to $62.00 and set an “equal weight” rating for the company in a report on Friday, July 28th. Wells Fargo & Company lowered their price target on shares of Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating for the company in a report on Friday, July 28th. Bank of America lowered their price target on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating for the company in a report on Friday, July 28th. Finally, SVB Securities initiated coverage on shares of Bristol-Myers Squibb in a report on Monday, July 10th. They issued a “market perform” rating and a $66.00 price target for the company. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $71.14.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock opened at $62.15 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.39 and a quick ratio of 1.28. Bristol-Myers Squibb has a 1-year low of $59.71 and a 1-year high of $81.43. The firm has a market capitalization of $129.84 billion, a P/E ratio of 16.53, a price-to-earnings-growth ratio of 1.61 and a beta of 0.42. The company’s 50-day moving average is $63.12 and its 200 day moving average is $66.77.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 EPS for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). The company had revenue of $11.23 billion for the quarter, compared to analysts’ expectations of $11.81 billion. Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The business’s revenue was down 5.6% compared to the same quarter last year. During the same period last year, the business posted $1.93 earnings per share. Research analysts forecast that Bristol-Myers Squibb will post 7.48 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date of this dividend was Thursday, July 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 60.64%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Robert M. Plenge sold 732 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the transaction, the executive vice president now directly owns 6,584 shares of the company’s stock, valued at $402,545.76. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See Also

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.